This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 429 studies, archived under the term: "USA"

Click here to filter this large number of results.

Comparing responses to horticultural-based and traditional activities in dementia care programs
Engaging persons with dementia in meaningful activities supports well-being; however, care staff are challenged to implement age- and ability-appropriate activities in a group setting. We compared a randomly assigned treatment group, who received horticultural therapy-based (HT-based) programming to a comparison group, who engaged in traditional activities (TA) programming, on engagement and affect. Horticultural therapy-based programming […]

Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention
Objectives: To test the effects of an intervention that helps families manage distressing behaviors in family members with dementia.; Design: Two-group randomized trial.; Setting: In home.; Participants: Two hundred seventy-two caregivers and people with dementia.; Intervention: Up to 11 home and telephone contacts over 16 weeks by health professionals who identified potential triggers of patient […]

The cost-effectiveness of a nonpharmacologic intervention for individuals with dementia and family caregivers: the tailored activity program
Objectives: To evaluate cost-effectiveness of the Tailored Activity Program (TAP) for individuals with dementia and family caregivers.; Design: Cost-effectiveness study of a two-group randomized controlled trial involving 60 patients-caregiver dyads randomized to intervention or wait-list control.; Setting: Participants’ homes in Philadelphia region.; Participants: Caregivers were aged ≥ 21 years, lived with patients, and provided ≥ […]

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis
Objective: To investigate the tolerability and efficacy of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease receiving concomitant memantine.; Research Design and Methods: Post hoc analysis of a 25-week, randomized, prospective, open-label, parallel-group study. Patients receiving donepezil were switched to rivastigmine patches (4.6 mg/24 h) immediately or following a 7-day withdrawal for 4 […]

Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms
The risk/benefit ratio of pharmacotherapy for behavioral symptoms of dementia is questionable: second-generation antipsychotics are poorly tolerated, and the efficacy of alternative treatments, for example, selective serotonin-reuptake inhibitors (SSRIs), is uncertain. Biomarkers of treatment response may improve this risk/benefit ratio. The length polymorphism of the serotonin transporter promoter gene (5-HTTLPR/SLC6A4) may moderate tolerability of SSRIs […]

Low-dose divalproex in agitated patients with Alzheimer’s disease
Adequate treatment of behavioral disturbances in Alzheimer’s disease is both important and difficult. This report describes a case series that examined the effectiveness and safety of low-dose divalproex in the treatment of agitated patients with Alzheimer’s disease who were admitted to an inpatient geriatric psychiatry unit over a 1-year period. All patients had agitation due […]

Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer’s disease: a retrospective analysis
Background: The Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) scale is widely used in Alzheimer trials. It assesses cognition, activities of daily living (ADLs), behavior and global functioning. To advance the understanding of relationships between the ADCS-CGIC and scores from other commonly used tools, this analysis investigated the ability of each domain to […]

Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer’s disease
Background and Objectives: Transdermal patches provide non-invasive, continuous drug delivery, and offer significant potential advantages over oral treatments. With all transdermal treatments a proportion of patients will experience some form of skin reaction. The rivastigmine patch has been approved for the treatment of mild-to-moderate Alzheimer’s disease (AD) since July 2007 in the US. The aim […]

Effect of donepezil on cognition in severe Alzheimer’s disease: a pooled data analysis
To better characterize response to donepezil in patients with severe AD, Severe Impairment Battery (SIB) data were pooled from four donepezil clinical trials (N=904). Changes in SIB total and domain scores from baseline to week 24 were compared between placebo and donepezil treatment groups (observed case analysis). Analyses were stratified by baseline severity (Mini-Mental State […]

Effects of rivastigmine in Alzheimer’s disease patients with and without hallucinations
Hallucinations in Alzheimer’s disease (AD) may indicate greater cortical cholinergic deficits. Rivastigmine has shown larger treatment benefits versus placebo in dementia with Lewy bodies and Parkinson’s disease dementia patients with hallucinations. In this retrospective, hypothesis-generating analysis, we investigated whether hallucinations in AD were associated with greater treatment benefits with rivastigmine. Data were pooled from two […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below:

�

Contact Us